-
Mashup Score: 27
Program: Oral and Poster Abstracts Type: Oral Session: 652. Multiple Myeloma: Clinical and Epidemiological: Molecular and Biological Signatures and Predictors of Outcomes Martin F. Kaiser, MD, FRCP, FRCPath 1,2, Rachel Phillip 3 *, Andrew Hall 3 *, Amy Holroyd 4 *, Laura Bevington 4 *, Ruth M de Tute, MSc, PhD, FRCPath 5 *, Laura Clayton 3 *, Sadie Roberts 3 *, Graham Jackson 6 *, Gordon Cook, PhD 7,8 *, Richard S Houlston 4 *, Mark Drayson 9 *, Roger Owen, MD, MRCP, FRCPath 10 *, Guy Pratt 11 *, Sarah R
Source: ash.confex.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 1Prospective Evaluation of Whole-Body MRI versus FDG PET/CT for Lesion Detection in Participants with Myeloma - 1 year(s) ago
To compare disease detection of myeloma using contemporary whole-body (WB) MRI and fluorine 18 ([18] F) fluorodeoxyglucose (FDG) PET/CT protocols and to correlate imaging with laboratory estimates of disease burden, including molecular characteristics.In …
Source: www.ncbi.nlm.nih.govCategories: General Medicine News, Oncologists2Tweet-
Myeloma WB-MRI is more sensitive than FDG-PET/CT https://t.co/w32e48bpTj MRI consistently detected more lesions than FDG-PET/CT, incl vertebra and long bones. Post-treatment scans showed response of all lesions only seen on WB-MRI, strongly suggesting they were true positives https://t.co/HQZT7y8x1U
-
-
Mashup Score: 0
Acknowledging the increasingly important role of whole-body MRI for directing patient care in myeloma, a multidisciplinary, international, and expert panel of radiologists, medical physicists, and hematologists with specific expertise in whole-body MRI in myeloma convened to discuss the technical pe …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Oncologists2Tweet-
Yes, early response can be assessed by WB-MRI (MY-RADS) – DW measures cellularity: lesions can be seen ‘melting’, before changing size. Image shows a tiny site of disease post-treatment (arrow in B), and clonal/focal patterns of re-growth (C). From https://t.co/X5duyCuTVP https://t.co/OIoKXiRWqe https://t.co/4dbYilM18X
-
-
Mashup Score: 0Low expression of hexokinase-2 is associated with false-negative FDG–positron emission tomography in multiple myeloma - 1 year(s) ago
Publisher’s Note: There is an on this article in this issue.[18] F-Fluorodeoxyglucose (FDG)–positron emission tomography (PET) and diffusion-weighted magnetic resonance imaging with background signal suppression (DWIBS) are 2 powerful functional …
Source: www.ncbi.nlm.nih.govCategories: General Medicine News, Oncologists2Tweet-
No, steroids don’t impact WB-MRI with diffusion weighting (DW). DW assesses tissue cellularity, not glucose consumption. Ca 10% of MM patients are FDG-PET/CT ‘false-negative’ vs WB-MRI, pot. due to HK2 deficiency (image). https://t.co/lK7lqsFbbb https://t.co/c8L3YK1El7 https://t.co/Zu6y8BFW8C
-
-
Mashup Score: 2Improving real‐world myeloma patient access to whole body MRI through “open‐access” knowledge sharing: The UK experience - 1 year(s) ago
As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: PMC Disclaimer | PMC Copyright
Source: www.ncbi.nlm.nih.govCategories: General Medicine News, Oncologists2Tweet-
Myeloma WB-MRI (MY-RADS) protocols are open access, for all major vendors, e.g. @SiemensHealth @generalelectric @philipshealthuk , link below. @ICIS_News and others run regular myeloma WB-MRI training workshops-virtual and in person (e.g. in London!) https://t.co/ffgi9FqAHv https://t.co/pNek5YOoeJ
-
-
Mashup Score: 4
Acknowledging the increasingly important role of whole-body MRI for directing patient care in myeloma, a multidisciplinary, international, and expert panel of radiologists, medical physicists, and hematologists with specific expertise in whole-body MRI in myeloma convened to discuss the technical performance standards, merits, and limitations of currently available imaging methods. Following guidance from the International Myeloma Working Group and the National Institute for Clinical Excellence in the United Kingdom, the Myeloma Response Assessment and Diagnosis System (or MY-RADS) imaging recommendations are designed to promote standardization and diminish variations in the acquisition, interpretation, and reporting of whole-body MRI in myeloma and allow response assessment. This consensus proposes a core clinical protocol for whole-body MRI and an extended protocol for advanced assessments. Published under a CC BY 4.0 license. Online supplemental material is available for this articl
Source: pubs.rsna.orgCategories: General Medicine News, Oncologists2Tweet-
Comment to Q1: No contrast needed for myeloma WB-MRI with diffusion weighting (MY-RADS, below). Also, no ionising radiation–important for renally impaired and patients who will have many scans in their life: SMM, EMD, oligo-/asecretory MM. https://t.co/hjEKzZ2vdr https://t.co/RCSLr6ocl0
-
-
Mashup Score: 13Weight-Loss Drugs Estimated to Save Airlines Millions - 1 year(s) ago
Airlines and planemakers obsess about reducing jet-fuel consumption by constantly finding new ways to reduce aircraft weight. They may have new allies in Ozempic and other similar slimming medications.
Source: www.bloomberg.comCategories: Latest Headlines, Oncologists2Tweet-
RT @BallouxFrancois: Well, that's an angle to the discussion on weight-loss drugs I hadn't considered ... 😐 https://t.co/sAjVueIDKo
-
-
Mashup Score: 19
Perspective from The New England Journal of Medicine — The New USPSTF Mammography Recommendations — A Dissenting View
Source: www.nejm.orgCategories: Latest Headlines, Oncologists2Tweet-
RT @EricTopol: New @NEJM Mass screening for breast cancer for women in their 40s makes no sense https://t.co/5zxR5R8G0W @StevenWoloshin and…
-
-
Mashup Score: 1ESH - European School of Haematology - 2 year(s) ago
7th Translational Research Conference: Multiple Myeloma October 04 – October 06, 2024 – Mandelieu-La Napoule, France – #ESHMM2024 Chairs : Hartmut Goldschmidt, Martin Kaiser, Suzanne Lentzsch Information 7th Translational Research…
Categories: Latest Headlines, Oncologists2Tweet-
RT @ESHaematology: 📣 #ESHMM2024 SAVE THE DATE: October 4-6, 2024 REGISTRATION IS OPEN, proceed here ➡ https://t.co/o6pN7YBzXv 📍 Join us in…
-
-
Mashup Score: 17Please wait whilst we redirect you - 2 year(s) ago
About ScienceDirectRemote accessShopping cartAdvertiseContact and supportTerms and conditionsPrivacy policyWe use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.Copyright © 2023 Elsevier B.V. or its licensors or contributors. ScienceDirect® is a registered trademark of Elsevier B.V.ScienceDirect® is a registered trademark…
Source: www.sciencedirect.comCategories: Latest Headlines, Oncologists2Tweet-
RT @mvmateos: AddThis | Home https://t.co/BbXa8TmS8G
-
Excellent summary - looking forward to #ASH23 - wonder whether in future *who* should be treated, in combination with *how* will be discussed more. We will present data on OPTIMUM and early #HRMM progressors - drop by Mon 2.45pm if of interest. https://t.co/wk0c0kRblt https://t.co/oaY18dy4z2